Global Amiodarone Injections Market Size, Share, and Trends Analysis Report, By Application (Atrial Fibrillation and Cardiac Arrest) and By End-user (Hospitals, Speciality Clinics, and Others), Forecast (2022-2028)

The global amiodarone injections market is anticipated to grow at a considerable CAGR 4% during the forecast period (2022-2028). Amiodarone injections belong to the antiarrhythmics class of medications that are used for the treatment of atrial fibrillation, a type of ventricular arrhythmias. The major factor attributing to the growth of the global amiodarone injections market includes the rising prevalence of atrial fibrillation across the globe. According to the report published by the National Center for Biotechnology Information (NCBI) in February 2021, atrial fibrillation is an irregular heart rate causing poor blood flow in the body. The organization estimates that around 6 million to 12 million people will be suffering from atrial fibrillation in the US alone by 2050. The report also describes that an estimation of around 17.9 million people will suffer from atrial fibrillation in Europe by 2060. There is some major risk associated with atrial fibrillation including ischemic strokes, morbidity, and mortality along with economic burden. Thus, increasing the demand for amiodarone injections for its treatment.

Additionally, the application of amiodarone injection is also increasing due to the rising cases of cardiac arrest across the globe. According to the Heart and Stroke Statistics 2022 report published by the American Heart Association (AHA), around 3.6 million out-of-hospital cardiac arrest events are recorded in the US every year. Among these, around 90% of the cases are non-fatal. It is estimated that around 1,000 people suffer from fatal or nonfatal cardiac arrest every day. Thus, boosting the demand for amiodarone injections.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in May 2020, the ProvideGx program of Premier Inc. partnered with Hikma Pharmaceuticals PLC to enhance the supply of two essential drugs for the treatment of COVID-19 patients was initiated. This program supplied amiodarone and sterile water to healthcare providers and stabilized the long-term supply of these essential drugs for COVID-19 patients.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By End-user
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Baxter International, Inc., AuroMedics Pharma LLC, Fresenius, Hikma Pharmaceuticals PLC, and Viatris Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Amiodarone Injections  Market Report by Segment

By Application

• Atrial Fibrillation
• Cardiac Arrest

By End-user

• Hospitals
• Speciality Clinics
• Others